One of the lowest paid CEOs in pharma—and the only woman leading a top-tier giant—is set to receive up to $27.2 million in ...

The move comes after President Donald Trump warned Big Pharma leaders that he would impose tariffs on them if they refuse to ...

The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...

While Kallyope’s drugs are mechanistically unique, the biotech is competing in a crowded space, with other therapies that ...

As they navigate a competitive job market, biopharma professionals are making four key interview mistakes, according to two ...

The back-to-back high-level disruptions in vaccine policy under Robert F. Kennedy Jr comes as the U.S. records its first ...

As communication gaps in the US healthcare market widen, the emphasis on the need for credible information and patient ...

Over 80% of those living outside of biopharma’s biggest hubs, like San Diego or Boston, have a tough time finding work, ...

In this episode of Denatured, BioSpace's Head of Insights Lori Ellis and Miruna Sasu, CEO of COTA, discuss life sciences investment and the potential for disruption.

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...

While many industry players and observers have high hopes for the EPIC Act, some say budgetary headwinds could make it ...

Kiniksa will now focus its development efforts on the IL-1 blocker KPL-387, which it is testing for recurrent pericarditis ...